Thermo Fisher Scientific has announced an expansion of its active pharmaceutical ingredient (API) manufacturing capabilities following the completion of its previously announced EUR 90-million ($100.6 million) acquisition of an API manufacturing facility from GlaxoSmithKline (GSK) in Cork, Ireland. Thermo Fisher had announced the acquisition in May (2019).

The site adds new API development and commercial capabilities and expands the company’s current API network of manufacturing facilities, which includes sites in Florence and Greenville South Carolina; Linz, Austria; and Regensburg, Germany. Approximately 400 employees at the Cork, Ireland, site will become part of Thermo Fisher’s Pharma Services API business and join Thermo Fisher’s 1,300 employees from its current sites.

This acquisition is part of Thermo Fisher’s overall strategy to further strengthen its pharma services business. In 2019, the company says it will invest more than $270 million to expand its capabilities, capacity and talent globally. This includes the recently announced opening of its new virtual reality training center in Greenville, North Carolina; expansion of its sterile fill–finish sites in Greenville, North Carolina, and Monza, Italy; expansion of its clinical trials supply and distribution capabilities in India, Argentina, and China; and expansion of its new viral vector manufacturing sites in Alachua, Florida, and Cambridge, Massachusetts. The company also plans to open a new viral vector manufacturing facility in Lexington, Massachusetts, later this year.

Source: Thermo Fisher Scientific